Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + temozolomide with or without SHR-1316 in relapsed small cell lung cancer
CTR20201115Phase 2Completed
- Sponsor
- Suzhou Shengdiya Biopharmaceuticals
- Start
- Jul 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib, temozolomide, adebrelimab in small cell lung cancer (SCLC), sponsored by Suzhou Shengdiya Biopharmaceuticals. Started Jul 2020; status: completed.
02
Drugs
fluzoparibtemozolomideadebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20201115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201115.